Diagnosis of disposition to malignant hyperthermia by an in vitro contracture test with phosphodiesterase-III-inhibitor enoximone;Diagnostik der disposition zur malignen hyperthermie durch einen in vitro kontrakturtest mit dem phosphodiesterase-III-hemmstoff enoximon

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 33, Issue 9, 1998, Pages 557-563

  Fiege, M ^a   Wappler, F ^a   Scholz, J ^a   Von Richthofen, V ^a   Brinken, B ^a   Schulte Am Esch, J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Caffeine; Enoximone; Halothane; Malignant hyperthermia; Phosphodiesterase

Indexed keywords

ANESTHETIC AGENT; CAFFEINE; ENOXIMONE; HALOTHANE; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; CALCIUM CELL LEVEL; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG MECHANISM; ENZYME INHIBITION; EXCITATION CONTRACTION COUPLING; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTURE; MUSCLE TWITCH; SECOND MESSENGER;

EID: 0031721259     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994811     Document Type: Article

References (43)

1. Gronert GA, Antognini JF: Malignant Hyperthermia. In: Anesthesia, 4th edition, ed. by Miller RD Churchill Livingstone 1994: 1075-1093
2. 2+ regulation defects. Physiol. Rev. 1996; 76: 537-592
3. Coronado R, Morissette J, Sukhareva M, Vaughan DM: Structure and function of ryanodine receptors. Am. J. Physiol. 1994; 266: C1485-C1504
4. Fill M, Coronado R, Mickelson JR, Vilven J, Ma J, Jacobsen BA, Louis CF: Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys. J. 1990; 50: 471-475
5. Fletcher JE, Tripolitis L, Erwin K, Hanson S, Rosenberg H, Conti PA, Beech J: Fatty acids modulate calcium-induced calcium release from skeletal muscle heavy sarcoplasmic reticulum fractions: Implications for malignant hyperthermia. Biochem. Cell. Biol. 1990; 68: 1195-1201
6. Foster PS, Gesini E, Claudianos C, Hopkinson KC, Denborough MA: Inositol-1,4,5-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine. Lancet 1989; II: 124-127
7. Scholz J, Troll U, Schulte am Esch J, Hartung E, Patten M, Sandig P, Schmitz W: Inositol-1,4,5-trisphosphate and malignant hyperthermia. Lancet 1991; 337: 1361
8. Wappler F, Scholz J, Köchling A, Steinfath M, Krause T, Schulte am Esch J: Inositol-1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia. Br. J. Anaesth. 1997; 78: 541-547
9. Stanec A, Stefano G: Cyclic AMP in normal and malignant hyperpyrexia susceptible individuals following exercise. Br. J. Anaesth. 1984; 56: 1243-1246
10. Willner JH, Cerri CG, Wood DS: High skeletal muscle adenylate cyclase in malignant hyperthermia. J. Clin. Invest. 1981; 68: 1119-1124
11. Ellis FR, Halsall PJ, Allam P, Hay E: A biochemical abnormality found in muscle from unstressed malignant-hyperpyrexia-susceptible humans. Biochem. Soc. Trans. 1984; 12: 357-358
12. Scholz H: PDE-Hemmung als therapeutisches Prinzip. Z. Kardiol. 1994; 83 Suppl. 2: 1-5
13. Schmitz W, von der Leyen H, Meyer W, Neumann J, Scholz H: Phosphodiesterase inhibition and positive motropic effects. J. Cardiovasc. Pharmacol. 1989; 14 Suppl. 3: 11-14
14. Hartung E, Rauch A, Rübsam B, Preis I, Sold M, Engelhardt W: Cyclic AMP and phosphodiesterase inhibition in skeletal muscle: a potent trigger or a cofactor for malignant hyperthermia? Minerva Anesthesiologica 1994; 60 Suppl. 3: 65-71
15. 2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients. Anesthesiology 1996; 84: 1280-1287
16. The European Malignant Hyperpyrexia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br. J. Anaesth. 1984; 56: 1267-1269
17. Ørding H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJA, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetmann E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol. Scand. 1997; 41: 955-966
18. Ørding H: Diagnosis of susceptibility to malignant hyperthermia in man. Br. J. Anaesth. 1988; 60: 287-302
19. Levitt RC: Prospects for the diagnosis of malignant hyperthermia susceptibility using molecular genetic approaches. Anesthesiology 1992; 76: 1039-1048
20. Hopkins PM, Halsall PJ, Ellis FR: Diagnosing malignant hyperthermia susceptibility. Anaesthesia 1994; 49: 373-375
21. Ørding H: Investigation of malignant hyperthermia susceptibility in Denmark. Dan. Med. Bull. 1996; 43: 111-125
22. Larach MG, Landis JR, Shirk SJ, Diaz M, The North American Malignant Hyperthermia Registry: Prediction of malignant hyperthermia susceptibility in low-risk subjects. Anesthesiology 1992; 77: A1052
23. Hopkins PM, Ellis FR, Halsall PJ: Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br. J. Anaesth. 1991; 66: 611-613
24. Lenzen C, Roewer N, Scholz J, Rumberger E, Schulte am Esch J: Ryanodin-induzierte Kontrakturen zur Diagnose der Maligne-Hyperthermie-Veranlagung. Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 1991; 26: 459-463
25. Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J: In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth. Analg. 1996; 82: 1230-1236
26. Hopkins PM, Ellis FR, Halsall PJ: Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders. Br. J. Anaesth. 1993; 70: 397-401
27. Herrmann-Frank A, Richter M, Lehmann-Horn F: 4-Cloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptibie and normal muscle. Biochem. Pharmacol. 1996; 52: 149-155
28. 2+ channel. Anesthesiology 1996; 84: 1380-1385
29. Ørding H, Glahn K, Gardi T, Fagerlund T, Bendixen D: 4-chloro-m-cresol test - a possible supplementary test for diagnosis of malignant hyperthermia susceptibility. Acta Anaesthesiol. Scand. 1997; 41: 967-972
30. Wappler F, Scholz J, von Richthofen V, Fiege M, Steinfath M, Schulte am Esch J: 4-Chloro-m-Cresol induziert Kontrakturen an Skelettmuskelpräparaten von Patienten mit Disposition zu maligner Hyperthermie. Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 1997; 32: 541-548
31. Halsall PJ, Ellis FR: Malignant hyperthermia. Curr. Anaesth. Crit. Care 1996; 7: 158-166
32. Nicholson CD, Challiss RAJ, Shahid M: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TiPS 1991; 12: 19-27
33. Wilke R, Arch JR, Nicholson CD: Tissue selective inhibition of cyclic nucleotide phosphodiesterase by denbufylline. Arzneimittelforschung 1989; 39: 665-667
34. Narindrasorasak S, Sanwal BD: Purification and polyamine activation of a high-affinity 3′,5′-cAMP phosphodiesterase from rabbit muscle. Biochem. Cell. Biol. 1986; 64: 930-935
35. m, cGMP-inhibited cAMP phosphodiesterase in cardiac and skeletal muscle. Biochem. Biophys. Res. Commun. 1996; 225: 1058-1062
36. 2-adrenoceptors in skeletal and cardiac muscle. Acta Anaesthesiol. Scand. 1993; 37: 575-583
37. McCarthy TV, Healy JMS, Heffron JJA, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-564
38. Steinfath M, Scholz J, Singh S, Wappler F: Welche Bedeutung haben Genotypveränderungen in der Diagnostik der malignen Hyperthermie? Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 1996; 31: 334-343
39. McCarthy TV, Quane KA, Ørding H, Urwyler A, Tegazzin V, Lehane M, Hartung E, Giblin LM, Lynch PJ, Vaughan P, Censier K, Bendixen D, Comi G, Fagerlund T, Wolz W, Heffron JJA, Müller CR, O'Halloran J, Manning BM: Genotype - phenotype correlation of mutations in the ryanodine receptor (RYR1) with the malignant hyperthermia IVCT. Proceedings of the Annual Meeting of the European Malignant Hyperthermia Group, Nijmegen 1997
40. Monnier N, Procaccio V, Stieglitz P, Lunardi J: A mutation in the human dihydropyridine receptor is associated with malignant hyperthermia susceptibility. Proceedings of the Annual Meeting of the European Malignant Hyperthermia Group, Nijmegen 1997
41. Jähnchen E, Trenk D: Pharmakologie und Pharmakokinetik von Enoximon. Z. Kardiol. 1991; 80 Suppl. 4: 21-26
42. Dage RC, Okerholm RA: Pharmacology and pharmacokinetics of enoximone. Cardiology 1990; 77 Suppl. 3: 2-13
43. Smith NA, Kates RE, Lebsack C, Ruder MA, Mead H, Bekele T, Okerholm RA, Rubin GM, Winkle RA: Clinical pharmacology of intravenous enoximone: Pharmacodynamics and pharmacokinetics in patients with heart failure. Am. Heart J. 1991; 122: 755-763